Key facts
- Biobot Surgical’s last known valuation is $54.3M (Mar 2024).
- It has raised $38.7M; the latest was Later Stage VC ($8.5M) in Apr 2026.
- Notable investors include ClavystBio, Andreas Handayanto, Ang Tiam, Astrid Hill Investment, Chia Chee Ming — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Biobot Surgical
- ·The full record, as it builds
Funding rounds
No funding rounds for Biobot Surgical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biobot Surgical
Developer of a robotic prostate biopsy and treatment system designed for improved clinical outcomes. The company provides complete prostate coverage, aided by robotic targeting and accurate biopsy needle positioning, enabling physicians to detect prostate cancer in patients early and providing confidence to enroll patients in an active surveillance program.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2007
- Employees
- 42
- Website
- biobotsurgical.com/
- Ownership
- Privately Held (backing)
Biobot Surgical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biobot Surgical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biobot Surgical in its N-PORT filings yet. We sweep new filings monthly.